Sidepocket: I read your post and feel you're sugarcoating things. I don't think my analysis of Gerald's performance versus what he said he'd do is off one bit! Where our stock price is today versus where Gerald intimated it would be suggests there has been a train wreck behind the scenes that we have not been told about.

I don't think LymPro is getting anywhere near the reception Gerald thought it would get. Maybe the multivariant numbers simply aren't good enough without the Georgetown tests bolstering them.

They basically don't have the money to exercise the ESS option without monetizing the diagnostic division. The problem is, it won't have any revenue to speak of by August 31st. So how much can they possibly get for it? I think Joe Rubenfeld led Gerald down a rat hole with this ESS thing and it's made shareholder stock values almost disappear!